Title	The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease
Author(s)	Yabe, Ichiro; Kitagawa, Mayumi; Takahashi, Ikuko; Matsushima, Masaaki; Sasaki, Hidenao
Citation	Clinical Neuropharmacology, 40(6), 261-263 https://doi.org/10.1097/WNF.0000000000000249
Issue Date	2017-11
Doc URL	http://hdl.handle.net/2115/71786
Rights	This is a non-final version of an article published in final form in Clinical Neuropharmacology, Volume 40, Issue 6, 2017, pp.261–263.
Type	article (author version)
File Information	ClinNeuropharmacol40_261.pdf

[Instructions for use](#)

Original article

The efficacy of istradefylline for treating mild wearing-off in Parkinson's disease

Ichiro Yabe, M.D., Ph.D.^{1*}, Mayumi Kitagawa, M.D., Ph.D.^{1,2}, Ikuko Takahashi, M.D.,
Ph.D.¹, Masaaki Matsushima, M.D., Ph.D.¹, Hidenao Sasaki, M.D., Ph.D.¹

¹Department of Neurology, Faculty of Medicine and Graduate School of Medicine,
Hokkaido University, Sapporo 060-8638, Japan

²Department of Neurology, Sapporo Teishinkai Hospital, Sapporo 065-0033, Japan

*Corresponding Author: Ichiro Yabe, Department of Neurology, Hokkaido University
Graduate School of Medicine

N15W7, Kita-Ku, Sapporo, Hokkaido 060-8368, Japan

Phone: +81-11-706-6028

Fax: +81-11-700-5356

E-mail address: yabe@med.hokudai.ac.jp

Running title: Efficacy of istradefylline in PD

Word counts of abstract: 207 words

Word counts of text: 888 words

Number of table: one

Number of figure: one

Number of references: 9

Conflicts of Interest and Source of Funding: none

Abstract

Objectives: The adenosine A_{2A} antagonist istradefylline has been used to treat Parkinson's disease (PD) with symptoms of wearing-off since 2013 in Japan. Previous randomized controlled trials (RCTs) of istradefylline compared with placebo included PD patients experiencing an average daily OFF time of ≥ 2 hours. The purpose of this study is to assess the efficacy of 20 mg/day istradefylline in PD subjects experiencing an average daily OFF time of ≤ 3 hours.

Methods: Fifteen patients were enrolled into this retrospective study. They received 20 mg/day istradefylline for 12 weeks. Changes in the Unified Parkinson's Disease Rating Scale part III scores in the ON state (ON-UPDRS-III) scores and daily OFF time were assessed at baseline and after 4, 8, and 12 weeks of administration of istradefylline.

Results: At baseline, all subjects had shorter daily OFF times, lower doses of L-DOPA and higher ON-UPDRS-III scores than those in previous RCTs. Twelve weeks of istradefylline significantly reduced ON-UPDRS-III scores ($p < 0.001$, Wilcoxon-signed rank test). Eleven patients (73%) showed more than 50% reductions in ON-UPDRS-III scores. Improvement of ON-UPDRS-III was significantly correlated with baseline

ON-UPDRS-III, and the mean ON-UPDRS-III score at endpoint was 12.1.

Conclusions: Our result suggests that 20 mg/day istradefylline significantly improved motor functions in PD patients with mild wearing-off.

Key words; Parkinson's disease, istradefylline, wearing-off

Introduction

Adenosine A2A antagonists facilitate dopamine D2 receptors and improve motor function in animal models of Parkinson's disease (PD) [1-3]. However, the effects of A2A antagonists, unlike the effects of dopamine agonists, depend on the dose of L-DOPA. A2A antagonists potentiate the effects of 'suboptimal' doses of L-DOPA without worsening dyskinesia [1,2], but that A2A antagonists with 'maximal' doses of L-DOPA are less effective [1].

Previous randomized controlled trials (RCTs) of the A2A antagonist istradefylline compared with placebo as an adjunct to L-DOPA have reported that showed that istradefylline significantly reduces both daily OFF time and ON-UPDRS-III, but the weighted mean difference in ON-UPDRS-III scores between 20 mg istradefylline and placebo is only -0.94 [4]. Two RCTs have reported a significant improvement in ON-UPDRS-III scores with the administration of 40 mg/day of istradefylline, but the changes from baseline was less than 5 [5-7]. These RCTs included PD patients experiencing an average daily OFF time of ≥ 2 , and mean daily OFF time at baseline of more than 6 hours.

Here, we report the efficacy of istradefylline 20 mg/day as an adjunct to L-DOPA in PD subjects experiencing an average daily OFF time of ≤ 3 hour.

Materials and Methods

This study was approved by the Institutional Review Board of Hokkaido University. Fifteen patients found to satisfy the following criteria were enrolled into this retrospective study from November, 2014 until November, 2016. All 15 patients were diagnosed with idiopathic PD according to the United Kingdom PD Society Brain Bank Diagnostic Criteria, with a modified Hoehn and Yahr Stage between 1 and 3 (in the OFF state), and had an average daily OFF time of ≤ 3 hours. All subjects were receiving L-DOPA, and the majority of them (80%) were receiving other PD medications. Three patients (20%) had developed dyskinesias. After giving informed consent, all subjects received 20 mg/day istradefylline for 12 weeks. The patients maintained usual levodopa and other anti-parkinsonian medications. Changes in the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III scores in the ON state (ON-UPDRS-III) scores and daily OFF time (MDS-UPDRS 4.3) were assessed at the baseline and at the end of

weeks 4, 8, and 12.

Results

At baseline, the subjects had shorter daily OFF times, lower doses of L-DOPA and higher ON-UPDRS-III scores than those in previous RCTs (Table 1) [5-7]. Mean tremor subscores at baseline, 4, 8 and 12 weeks were 1.8, 0.7, 0.6 and 0.4, respectively. Mean rigidity subscores at baseline, 4, 8 and 12 weeks were 6.0, 2.8, 2.6 and 2.3, respectively. Mean akinesia subscores at baseline, 4, 8 and 12 weeks were 13.7, 7.7, 7.5 and 6.4, respectively. After 12 weeks of istradefylline administration, 11 patients (73%) showed more than 50% reductions in ON-UPDRS-III scores, and there was a significant reduction in ON-UPDRS-III scores ($p < 0.001$, Wilcoxon-signed rank test). Improvement of ON-UPDRS-III was significantly correlated with baseline ON-UPDRS-III (Figure1, Spearman's correlation coefficient $\rho = 0.7671$, $p < 0.001$), but not with age, the duration of the disease, levodopa dosage or ON-UPDRS-III after 12 weeks administration of istradefylline. The mean ON-UPDRS-III score at endpoint was 12.1. Istradefylline tended to reduce the daily OFF time ($p = 0.06$). Dyskinesias

developed in two patients, and worsened in two other patients. Mean dyskinesia subscores at baseline, 4, 8 and 12 weeks were 0.3, 0.3, 0.2 and 0.4, respectively.

Discussion

Twenty mg/day of istradefylline dramatically improved ON-UPDRS-III scores in PD patients with mild wearing-off. The high responder rate in this study may help us to understand the factors influencing clinical effects of istradefylline on parkinsonian motor symptoms despite the small number of subjects.

L-DOPA dosage and age at disease onset have been reported to influence on the occurrence of motor fluctuations [8]. One of the authors of this paper has previously reported that a chronic low-dose levodopa treatment proved satisfactory benefit with a low incidence of motor complications in Japanese PD patients [9]. Because the subjects in the present study had older age at disease onset and were treated with low dosages of L-DOPA despite of higher ON-UPDRS-III scores than those in the previous RCTs, older age at onset and low (suboptimal) L-DOPA dosages may be associated with stable response to L-DOPA. It should be noted that more severely affected patients showed

greater improvement in ON-UPDRS-III, which suggests that istradefylline can potentiate the effects of “sub-threshold” dosage of L-DOPA above the threshold (Figure 1). Although a few previous RCTs have not shown a statistically significant reduction in OFF time because of a placebo effect [6], many other RCTs have revealed that istradefylline 20 mg/day, 40 mg/day and 60 mg/day significantly reduce daily OFF time. The present results suggest that istradefylline 20 mg/day can reduce daily OFF time in PD patients with mild wearing-off. Further evaluations of early use of istradefylline combined with “sub-optimal” L-DOPA in controlled clinical trials are needed.

The present study, as well as previous animal studies, suggests that adding istradefylline to low doses of L-DOPA and dopamine agonists is superior to the later use in PD patients treated with high doses of L-DOPA. It may be effective to administer istradefylline before the off symptoms progress.

Limitations

This study is limited by the fact that it is retrospective. Further evaluations on the early use of istradefylline combined with low doses of L-DOPA in double blinded

randomized controlled clinical trials are naturally needed.

Acknowledgements

We would like to thank the patients for their participation in this study.

Potential conflict of interest

No conflict of interest

Author contributions

Yabe and Kitagawa had full access to all of the data in the study. Study concept and

design: Yabe and Kitagawa. Acquisition of data: Yabe, Takahashi, and

Matsushima. Statistical analysis: Kitagawa. Analysis and interpretation of data: Yabe

and Kitagawa. Drafting of the manuscript: Yabe and Kitagawa. Critical revision of

the manuscript for important intellectual content: Takahashi, Matsushima, and Sasaki.

Study supervision: Sasaki.

References

- [1] Rose S, Ramsay Croft N, Jenner P. The novel adenosine A_{2a} antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats. *Brain Res* 2007; 1133: 110-114.
- [2] Uchida S, Tashiro T, Kawai-Uchida M, Mori A, Jenner P, Kanda T. Adenosine A₂ A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets. *J Pharmacol Sci* 2014; 124: 480-485.
- [3] Bibbiani F, Oh JD, Petzer JP, Castagnoli N Jr, Chen JF, Schwarzschild MA, Chase TN. A_{2A} antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. *Exp Neurol* 2003;184: 285-294.
- [4] Chen W, Wang H, Wei H, Gu S, Wei H. Istradefylline, an adenosine A₂ A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis. *J Neurol Sci* 2013; 324: 21-28.
- [5] Hauser RA, Hubble JP, Truong DD; Istradefylline US-001 Study Group. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in

advanced PD. *Neurology* 2003; 61: 297-303.

- [6] Pourcher E, Fernandez HH, Stacy M, Mori A, Ballerini R, Chaikin P. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study: Adenosine A2A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets. *Parkinsonism Relat Disord* 2012; 18: 178-184.
- [7] Mizuno Y, Kondo T; Japanese Istradefylline Study Group. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. *Mov Disord* 2013; 28: 1138-1141.
- [8] Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. *Arch Neurol* 2006; 63:1756-1760.
- [9] Kitagawa M, Tashiro K. Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study. *Intern Med* 2005; 44: 939-943.

Figure Legend

Figure 1. The correlation between the changes in ON-UPDRS-III and ON-UPDRS-III scores at baseline or after 12 weeks administration of istradefylline.

Improvement of ON-UPDRS-III was significantly correlated with baseline ON-UPDRS-III (Spearman's correlation coefficient $\rho = 0.7671$, $p < 0.001$), but not with ON-UPDRS-III after 12 weeks administration of istradefylline.

ON-UPDRS-III

Table 1. Comparison of the present study and previous studies.

	Present Study	Hauser (2008)	Pourcher (2012)	Mizuno (2013)
Study design	Case study	RCT	RCT	RCT
Number of patients	15	115	149	120
Inclusion criteria				
Hoehn and Yahr stage	1-3	2-4	2-4	2-4
Daily OFF time (hours)	≤ 3	≥ 3	≥ 3	≥ 2
Baseline characteristics				
Age (years), mean (SD)	70.1 (6.0)	63.0 (9.5)	64.0 (9.3)	66.1 (8.6)
Disease duration (years), mean (SD)	9.1 (6.0)	10.0 (5.5)	8.9 (4.6)	7.3 (4.2)
Daily OFF time (hours), mean (SD)	1.4 (0.6)	6.7 (2.8)	6.7 (2.2)	6.5 (2.7)
ON-UPDRS-III score, mean (SD)	29.7 (9.1)	23.9 (11.3)	22.3 (11.3)	21.3 (10.8)
Daily ON time with Dyskinesia (hour), mean (SD)	0.3 (0.6)	2.8 (3.6)	N/A	1.6 (2.8)
L-DOPA (mg/day), mean (SD)	395 (217)	652 (371)	602 (357)	431 (157)
Mean changes from baseline to endpoint				
ON-UPDRS-III score	-17.6*	-3.2	-0.8	-3.7
Daily OFF time (hours)	-0.5	-1.6#	-1.1	-0.99##

Baseline vs Endpoint: * p < 0.001

Istradefylline vs Placebo: # p < 0.05, ## p < 0.01

N/A, not applicable